首页> 外文OA文献 >Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

【2h】

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

机译：强化第一线FIR-C / Fox-C三重素化疗协会加入野生型转移性结肠直肠癌患者的西妥昔单抗：药物生物标志物预测的初期阶段II数据和个体限制毒性综合征

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
G. Bruera; S. Massacese; F. Pepe; U. Malapelle; A. Dal Mas; E. Ciacco; G. Calvisi; P. Marchetti; G. Troncone; M. Simmaco; E. Ricevuto;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers [J] . Gemma Bruera, Silvia Massacese, Francesco Pepe, Therapeutic advances in medical oncology. . 2019,第12期

机译：RAS野生型转移性结直肠癌患者的三联化疗加入西妥昔单抗的密集第一线FIR-C / FOX-C协会：药物孕母标综合症的初步期II数据和预测个体限制毒性综合征
2. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial (vol 31, pg 2477, 2013) [J] . Siu L. L., Shapiro J. D., Jonker D. J. Journal of Clinical Oncology . 2015,第18期

机译：西妥昔单抗联合布兰替尼丙氨酸盐与西妥昔单抗联合安慰剂在转移性，化疗难治性野生型K-RAS大肠癌患者中进行的III期随机，安慰剂对照研究：NCIC临床试验小组和AGITG CO.20试验（第31卷， pg 2477，2013）
3. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial (vol 31, pg 2477, 2013) [J] . Siu L. L., Shapiro J. D., Jonker D. J. Journal of Clinical Oncology . 2015,第18期

机译：III期随机，安慰剂对照对甲嘧啶加温凡纳替代的丙烷类丙烷酸二甲酸盐，化疗 - 难治性，野生型K-RAS结直肠癌患者：NCIC临床试验组和Agitg Co.20试验（Vol 31， PG 2477,2013）
4. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers [O] . Gemma Bruera, Silvia Massacese, Francesco Pepe, 2019

机译：RAS野生型转移性结直肠癌患者中三重化疗加西妥昔单抗的一线强化FIr-C / FOx-C关联：II期初步数据和通过药物基因组生物标志物预测的个体限制性毒性综合征
5. Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease [O] . Gemma Bruera, Enrico Ricevuto 2020

机译：毒性综合征，胃肠癌中胃肠癌中胃肠癌强度诱导毒性负担的患者相关临床指标

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

著录项

引文网络

相似文献

相关主题

期刊订阅